T. Rowe Price Associates
DMAC icon

T. Rowe Price Associates’s DiaMedica Therapeutics DMAC Stock Holding History

T. Rowe Price Associates’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Buy
30,492
+7,322
+32% +$45K ﹤0.01% 2985
2026
Q1 		$157K Buy
23,170
+3,510
+18% +$27.8K ﹤0.01% 2902
2025
Q4 		$157K Hold
19,660
– – ﹤0.01% 2865
2025
Q3 		$136K Buy
19,660
+6,292
+47% +$34.1K ﹤0.01% 2870
2025
Q2 		$53K Buy
+13,368
New +$52.1K ﹤0.01% 2997

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

T. Rowe Price Associates's DMAC Position: Q2 2026 in Review

T. Rowe Price Associates increased its DiaMedica Therapeutics (DMAC) stake by 32% in Q2 2026, buying an estimated $45K and bringing the position to 30,492 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

T. Rowe Price Associates first reported a position in DMAC in Q2 2025 and has held it in 5 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • T. Rowe Price Associates held 30,492 shares of DiaMedica Therapeutics worth $215K as of Q2 2026.
  • T. Rowe Price Associates bought 7,322 DiaMedica Therapeutics shares in Q2 2026, an estimated $45K.
  • DiaMedica Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2985 holding.
  • T. Rowe Price Associates first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.